Apolipoprotein E (apoE) plays a role in the pathogenesis of Alzheimer disease (AD). It is involved in the receptor-mediated cellular clearance of the amyloid A-protein (AA) and in the perivascular drainage of the extracellular fluid. Microvascular changes are also associated with AD and have been discussed as a possible reason for altered perivascular drainage. To further clarify the role of apoE in the perivascular and vascular pathology in AD patients, we studied its occurrence and distribution in the perivascular space, the perivascular neuropil, and in the vessel wall of AD and control cases with and without small vessel disease (SVD). Apolipoprotein E was found in the perivascular space and in the neuropil around arteries of the basal ganglia from control and AD cases disclosing no major differences. Western blot analysis of basal ganglia tissue also revealed no significant differences pertaining to the amount of fulllength and C-terminal truncated apoE in AD cases compared with controls. In contrast, AA occurred in apoE-positive perivascular astrocytes in AD cases but not in controls. In blood vessels, apoE and immunoglobulin G were detected within the SVD-altered vessel wall. The severity of SVD was associated with the occurrence of apoE in the vessel wall and with that of AA in perivascular astrocytes. These results point to an important role of apoE in the perivascular clearance of AA in the human brain. The occurrence of apoE and immunoglobulin G in SVD lesions and in the perivascular space suggests that the presence of SVD results in plasma-protein leakage into the brain. It is therefore tempting to speculate that apoE represents a pathogenetic link between SVD and AD.
INTRODUCTION
The deposition of the amyloid A-protein (AA) and the formation of neurofibrillary tangles are histopathologic hallmarks of Alzheimer disease (AD) (1Y3). Amyloid Aprotein deposition can either result from an increased production or aggregation, as seen in familial AD cases, and in transgenic mice or from altered AA clearance (4Y11). Important clearance mechanisms for AA include the cellular clearance by microglial cells and astrocytes (12Y17), degradation by proteases such as neprilysin and the insulin-degrading enzyme (6, 18) , clearance via the blood-brain barrier (BBB) (9) , and drainage along perivascular channels (8) .
Apolipoprotein E (apoE) is a plasma lipoprotein constituent that is produced in the liver (19) . In the brain, astrocytes and neurons are capable of producing apoE (20, 21) . Recently, we have reported that apoE occurs in perivascular drainage channels of wild-type and amyloid precursor protein (APP)Y transgenic mice (22) . Because the APOE ?4 allele is a major risk factor for sporadic AD (23) , apoE binds AA (24, 25) , and because the > 2 -macroglobulin receptor/low-density lipoprotein receptor-related protein (LRP) is an important receptor for the uptake of apoE-bound AA by neurons and astrocytes (26, 27) , it has been speculated that binding of apoE to AA is critical for AA clearance. In fact, LRP is considered to be involved in AA clearance through the BBB (9) . Perivascular drainage of AA has been discussed as a further mechanism for AA clearance (8) . This is supported by the presence of cerebrovascular AA deposits in the human brain and in the brains of transgenic mice producing AA almost exclusively in nerve cells (8, 28) . The colocalization of AA and apoE within the perivascular space of APP-transgenic mice also argues in favor of an apoElinked perivascular clearance of AA (22) . In this context, however, it has not been shown whether perivascular spaces in the human brain similarly contain apoE and AA and contribute to AA clearance.
Cerebral small vessel disease (SVD) is associated with AD (29Y32). Such vascular alterations have been discussed to impact perivascular drainage and BBB function in the brain (8, 33, 34) . Although these associations have been reported, a clear pathogenetic link between AD and SVD has not been described so far.
Here, we analyzed the distribution of apoE and AA in the perivascular neuropil, the perivascular space, and in intracerebral arteries and veins. Our results provide evidence for the contribution of apoE to both the perivascular clearance of AA in the human brain and the development of SVD and suggest a pathogenetic link between SVD and AD.
MATERIALS AND METHODS

Neuropathology
Thirty human autopsy cases (10 AD and 20 non-AD cases; Table) studied extensively for the presence and 2  0  0  B  0  0  3/3  17  79  F  2  Multiple hemorrhagicinfarcts; AGD  2  0  0  C  0  0  3/3  18  83  F  0  Arteriosclerosis; AGD  3  0  1  C  1  2  3/3  19  84  F  0  Arteriosclerosis; multiple hemorrhagic  infarcts; AGD   1  0  1  B  0  0  2/3   20  88  M  2  AGD  2  1  3  B  1  2  2/3  21  78  M  1  AD; CAA  4  1  3  B  1  2  3/3  22  78  F  3  AD; M. Fahr  5  2  4  B  2  2  3/4  23  81  F  3  AD; CAA  5  2  4  C  1  2  3/3  24  82  M  2  AD; arteriosclerosis  3  2  3  C  2  2  3/4  25  83  M  3  AD; old infarction; CAA; small pontine  hemorrhage   5  2  4  B  3  2  4/4   26  83  M  3  AD; small pseudocystic infarct; plexus  choroideus xanthogranuloma   4  2  4  B  2  2  3/3   27  85  M  2  AD; microinfarcts; CAA; mixed dementia  3  2  3  C  3  2  3/4  28  87  F  3  AD; CAA; arteriosclerosis  4  1  4  C  2  2  3/3  29  89  F  3  AD; CAA  5  3  4  C  2  2  3/4  30  89  F  2  AD; CAA; mild arteriosclerosis  4  3  4  B  2  2  3/4  b: Cases used for biochemical analysis  31  66  M  0  Intracerebral and subarachnoidal  hemorrhage   1  0  0  B  0  0  3/3   32  70  M  0  Control  1  0  0  B  0  0  2/3  33  71  F  0  Microinfarction  1  0  0  B  0  0  2/3  34  71  M  0  CAA; SVD  2  0  2  C  1  2  2/4  35  77  F  3  Vascular dementia; pontine hemorrhage  3  1  2  B  0  0  3/3  36  80  F  0  Hypertensive arteriopathy; CAA  2  0  2  C  1  1  3/4  37  62  F  3  AD  6  3  4  B  1  1  3/4  38  64  F  ND  AD; hypertensive arteriopathy  6  3  4  A  1  2  3/4  39  79  F  ND  AD; microinfarction  4  2  3  B  1  2  3/3  40  84  M  3  AD; DLB  6  3  4  B  2  1  3/4  41  91  F  3  AD  4  2  3  C  0  0  ND AA, Amyloid A-protein; AD, Alzheimer disease; AGD, argyrophilic grain dementia; APOE, apolipoprotein E; CAA, cerebral amyloid angiopathy; CDR, Clinical Dementia Rating (73); CERAD, Consortium to Establish a Registry for Alzheimer's Disease score (43) ; DLB, dementia with Lewy bodies; ND, not determined; SVD, small vessel disease. distribution of AD-related changes as published earlier (35) were used to study the distribution of AA, apoE, LRP, and immunoglobulin G (IgG) in the basal ganglia.
Demented and nondemented patients had been examined 1 to 4 weeks prior to death according to standardized protocols used for routine clinical and neurologic examination of patients upon admission to the hospital. The protocols included the assessment of cognitive function and recorded the ability to care for and dress oneself, eating habits, bladder and bowel continence, speech patterns, writing and reading skills, short-term and long-term memory, and the orientation within the hospital setting. The Clinical Dementia Rating score (36) was observed retrospectively. These data were used to determine whether individuals clinically fulfilled the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria for dementia (37) or not. Alzheimer disease diagnosis was given in the event that dementia was observed, and AD-related pathology fulfilled recommended criteria for the diagnosis of AD at autopsy (38) .
The brains were fixed in a 4% aqueous formaldehyde solution for at least 3 weeks. For the diagnosis of AD-related changes, blocks of the right medial temporal lobe (MTL) were taken at the levels of the 1) anterior limit of the dentate gyrus, 2) lateral geniculate body, and 3) posterior limit of the dentate gyrus (39) . The tissue blocks were embedded in polyethylene glycol (Merck-Schuchardt, Hohenbrunn, Germany) (40) and in paraffin. The polyethylene glycol blocks were microtomed at 100 Km, whereas the paraffin sections were cut at 10 Km. Blocks from the basal ganglia, including putamen, globus pallidum, internal and external capsule, claustrum, and the insular cortex, were embedded in paraffin from each case, and 10-Km sections were cut.
Neurofibrillary changes were detected using the Gallyas silver staining method (40, 41) . Abnormal phosphorylated tau-protein was recognized with a monoclonal antibody (AT-8; Innogenetics, Ghent, Belgium; 1/1000). The presence of amyloid deposits was assessed using the Campbell-Switzer silver impregnation method (40, 41) and/or using immunohistochemistry with an antibody directed against AA 17Y24 (4G8; Covance, Emeryville, CA; 1/5000; formic acid pretreatment). For topographic orientation and neuropathologic diagnosis, serial paraffin and polyethylene glycol sections were stained with aldehyde fuchsin-Darrow-red for lipofuscin pigment and Nissl material. Cytoarchitectural and pigmentoarchitectural parcellation of the entorhinal layers were performed according to Braak and Braak (42) . Diagnosis of the stages in the development of neurofibrillary changes (Braak stage) was performed in accordance with published criteria (2, 38) . The frequency of neuritic plaques (Consortium to Establish a Registry for Alzheimer's Disease score) was assessed as recommended by Mirra et al (43) on Gallyas-stained sections. For the Braak staging, Consortium to Establish a Registry for Alzheimer's Disease scores, and staging of cerebral amyloid angiopathy (CAA), additional sections from the occipital cortex, including the primary visual cortex, were analyzed. For staging of AA pathology, we used the recently described 4 phases of A-amyloidosis in the MTL (44) . This hierarchically based procedure enables us to explore the expansion of AA-deposition into additional brain regions (44, 45) . Phase 1 represents AA deposits that are restricted to the temporal neocortex. Phase 2 is characterized by additional AA plaques in the entorhinal cortex and/or in the subiculum-CA1 region. The third phase of A-amyloidosis exhibits additional AA plaques in the outer zone of the molecular layer of the fascia dentata, subpial band-like amyloid, and/or the presubicular Blake-like[ amyloid. The presence of additional AA plaques in CA4 and/or the pre-> layer of the entorhinal cortex mark the fourth and final phase of AA deposition in the MTL.
The overall expansion of CAA in all autopsy cases was determined according to the 4 stages reported for the development of CAA (30): Stage 0, no CAA; Stage 1, CAA is restricted to neocortical vessels; Stage 2, CAA is seen in neocortical and allocortical vessels and/or in cerebellar vessels; and Stage 3, CAA occurs in the neocortex and allocortex, the cerebellum, the striatum, and in the thalamus. Anti-AA-stained or Campbell-Switzer-stained sections of appropriate regions were analyzed.
The severity of CAA was determined in sections of the MTL, occipital cortex, and the basal ganglia. The most severe lesions in these sections were graded according to previously published criteria (46) as follows: 0 (normal), no CAA; 1 (mild), AA deposits in the vessel wall without loss of smooth muscle cells in the vessel wall; 2 (moderate), AA deposits in the vessel wall accompanied by degeneration of the smooth muscle cell layer; and 3 (severe), extensive AA deposition and focal vessel wall fragmentations, microaneurysms, signs of hemorrhage, and fibrinoid necrosis.
Stages for SVD were determined as previously published: SVD Stage 0, no SVD; A, SVD in the basal ganglia; B, SVD also in the thalamus, basal forebrain, cortex, cerebellum, and the amygdala; C, in addition to the regions affected in Stages A and B, SVD occurs in the brainstem and in the hypothalamus. Hematoxylin and eosin, elastica van Gieson, aldehyde fuchsin-Darrow-red, and anti-AA 17Y24 -stained sections were used to categorize the basal ganglia sections neuropathologically.
Immunohistochemistry
Paraffin sections (10-Km thick) from the basal gangliawere immunostained with antibodies raised against AA 17Y24 (4G8), a synthetic peptide spanning the polymorphic amino acid position 158 of apoE (D6E10; Covance; 1/500; microwave and formic acid pretreatment), the last 15 amino acids of LRP (LRP-1704; polyclonal rabbit antibody [47] 1/50; microwave pretreatment), LRP CD91->-chain (>2-M-R-II2C7; BioMac, Leipzig, Germany; 1/150; microwave and protease pretreatment), and human IgG (polyclonal goat; Biomeda, Foster City, CA; 1/100; microwave pretreatment). Biotinylated secondary antibodies (avidin-biotin-peroxidase complex kit; Biomeda) were used to detect the primary antibodies and were visualized with the avidin-biotin-peroxidase complex (avidin-biotin-peroxidase complex kit; Biomeda), 3,3-diaminobenzidine-HCl (Sigma-Aldrich, Taufkirchen, Germany), and counterstained with hematoxylin. Positive and negative controls were performed routinely to ensure adequate staining quality.
To verify the presence of AA and/or apoE in perivascular astrocytes, smooth muscle cells, and perivascular macrophages and to assess a colocalization of both proteins, double label immunofluorescence has been performed. The term perivascular astrocytes describes astrocytes that are located near the perivascular (Virchow-Robin) space and have processes that contribute to the glial border between the brain and the perivascular space (Figs. 1K, N). Perivascular macrophages are those located within the perivascular space. To test whether AA and/or apoE occurs in perivascular astrocytes, we used antibodies directed against the glial fibrillary acidic protein (GFAP; polyclonal rabbit; DAKO, Hamburg, Germany; 1/1000) to detect the astrocytes and anti-AA 17Y24 (4G8) or anti-apoE (D6E10). Carbocyanin (Cy)-labeled secondary antibodies (Dianova, Hamburg, Germany) specifically detecting mouse or rabbit IgG were applied in a cocktail. Carbocyanin 2-or Cy3-labeled anti-rabbit IgG and Cy2-or Cy3-labeled anti-mouse IgG were used. For the simultaneous detection of AA 17j24 and apoE, smooth muscle actin (1A4; DAKO; 1/200; microwave pretreatment) and apoE as well as the microglial and macrophage marker CD-68 (PG-M1; DAKO; 1/100; heat pretreatment) and apoE anti-AA 17Y24 , anti-smooth muscle actin, or anti-CD-68 were applied first and were then visualized with a Cy2-or Cy3-labeled antimouse IgG antibody. Subsequently, after absorption of free mouse IgG, the second primary antibody against apoE was applied and visualized with Cy2-or Cy3-labeled anti-mouse IgG. Sections were viewed with a Leica-DMLB fluorescence microscope and a Leica TCS NT confocal laser scanning microscope (Leica, Bensheim, Germany).
Quantitative Western Blot Analysis of apoE in the Basal Ganglia
Fresh tissue from the basal ganglia covering the putamen and the globus pallidus of 1 hemisphere was dissected at autopsy and stored frozen at j80-C until further use. Western blot analysis was performed for 5 AD and 6 control cases (Table; Cases 31Y41). The other hemisphere was fixed in a 4% aqueous solution of formaldehyde and processed similarly as described for Cases 1 to 30.
For Western blot analysis, frozen tissue was homogenized in lysis buffer containing 1% Triton X-100 and 1% NP-40. Lysates were centrifuged at 13,200 rpm for 30 minutes at 4-C to obtain supernatants and pellets. Pellets were further resuspended in lysis buffer and homogenized. Supernatants and resuspended pellets were subjected separately to sodium dodecyl sulfate-urea polyacrylamide gel electrophoresis and analyzed by Western immunoblotting with anti-apoE (D6E10) antibody. Actin was detected as loading control.
Using the ImageJ software for densitometric measurements (National Institutes of Health, Bethesda, MD), bands for full-length and C-terminal truncated apoE were measured, and for the pellets, a ratio of C-terminal truncated apoE/fulllength apoE was calculated. Cases with a ratio higher than 1 were categorized as C-terminal truncated apoE predominant, and those with a ratio smaller than 1 were categorized as fulllength apoE predominant. None of the cases analyzed had a ratio equal to 1.
Semiquantitative Assessment of Perivascular AA, apoE, LRP, and IgG
To determine the amount and distribution of apoE and AA within the vessel wall, the perivascular space, and in the neighboring neuropil, we semiquantitatively assessed whether and to which degree the perivascular space, neuropil, and the vessel walls were stained with anti-apoE, anti-AA 17Y24 , and anti-LRP in sections from the basal ganglia. The semiquantitative assessment of LRP expression was performed separately for the >-chain and the C-terminus as detected with the respective antibodies. The following criteria were used for the semiquantitative assessment of the apoE, LRP, IgG, and AA expression in the perivascular space, perivascular astrocytes, and within the vessel wall.
For apoE, LRP, IgG, and AA expression in the perivascular space, 0 indicates no positive material in the perivascular space; 1, the perivascular space contains immunopositive material in up to and including 25% of the vessels of the putamen and the globus pallidus; 2, the perivascular space contains immunopositive material in 26% to 50% of the vessels of the putamen and the globus pallidus; 3, more than 50% of the vessels of the putamen and the globus pallidus contain immunopositive material.
For apoE, LRP, IgG, and AA expression in perivascular astrocytes, 0 indicates no immunopositive material in perivascular astrocytes; 1, 1 to 3 astrocytes contain immunopositive material in less than 25% of the vessels in the putamen and the globus pallidus; 2, more than 3 astrocytes contain immunopositive material in less than 50% of the vessels in the putamen and the globus pallidus; 3, more than 3 astrocytes contain immunopositive material in more than 50% of the vessels in the putamen and the globus pallidus.
For apoE, LRP, IgG, and AA expression in the vessel wall, 0 indicates no vascular immunopositive material; 1, 1 to 3 vessels with mild affection/expression (G20% of the vessel wall exhibit immunopositive material); 2, 1 to 3 vessels with moderate affection/expression (920% of the vessel wall exhibit immunopositive material); and 3, more than 3 vessels with moderate to severe affection/expression (920% of the vessel wall exhibit immunopositive material). Statistical tests were calculated with the SPSS 14.0 program (SPSS, Chicago, IL).
APOE Genotyping
Genomic DNA was extracted either from unfixed frozen brain tissue or from the paraffin-embedded cerebellar cortex. For suitable DNA templates, a 1-step polymerase chain reaction was used, followed by the standard restriction isotyping with the restriction enzyme HhaI (48). For DNA templates from formaldehyde-fixed specimens, a seminested polymerase chain reaction assay was used (49) . This method facilitates reliable APOE genotyping of DNA from archival tissue specimens by enhancing the yield of the polymerase chain reaction product.
RESULTS
Occurrence of apoE and AA in the Perivascular Space and in Perivascular Astrocytes
Apolipoprotein E was detected in the perivascular space and in perivascular astrocytes of both AD and control cases (Fig. 1A) . Amyloid A-protein was only seen in perivascular astrocytes of AD cases but not in the controls (Figs. 1B, C) . Within the perivascular space, AA was detected only in 3 AD (Figs. 1D, F ) and 2 non-AD cases. Double label immunofluorescence indicated colocalization of AA and apoE within the perivascular space (Figs. 1DYF) . Perivascular astrocytes positive for AA also exhibited apoE (Figs. 1GYI; arrows) . The occurrence of apoE and AA in perivascular astrocytes was confirmed by double label immunohistochemistry with anti-GFAP (Figs. 1JYO) . However, a high number of GFAP-positive perivascular astrocytes did not exhibit anti-apoE-or anti-AApositive material (Figs. 1MYO) . The serum in the blood vessel lumen exhibited apoE and mildly AA-positive material (Figs. 1DYI, MYO; asterisks).
Semiquantitative assessment confirmed the general presence of AA within perivascular astrocytes in the basal ganglia of AD cases in comparison to that of nondemented controls (Mann-Whitney U test, p G 0.001; Fig. 2A (2) . Apolipoprotein E-positive astrocytes occurred in AD and in control brains (Mann-Whitney U test, p = 0.12; Fig. 2A ). Significant differences in the apoE expression in perivascular astrocytes among the AA phases in the MTL (p = 0.13), the CAA stages (p = 0.51), and the Braak stages (p = 0.395) were not observed. There were no evident differences in the occurrence of apoE and AA within the perivascular space of AD cases and nondemented individuals (Mann-Whitney U test: apoE, p = 0.267; AA, p = 0.374; Fig. 2B ). Amyloid Aprotein-positive material within the perivascular space was thereby found in 3 AD and 2 non-AD cases.
Amyloid A-protein-positive perivascular astrocytes were more frequently found in APOE ?4 carriers (MannWhitney U test; p G 0.05), whereas there were no major differences in the occurrence of apoE in the perivascular space (Mann-Whitney U test; p = 0.505) and in perivascular astrocytes among the APOE genotypes (Mann-Whitney U test; p = 0.866).
LRP Expression in Perivascular Astrocytes of AD and Control Cases
Perivascular astrocytes were immunostained with anti-LRP-1704 directed against the C-terminus of LRP and with anti-LRP-CD91 >-chain in similar patterns in AD and control cases (Fig. 3) . Likewise, the expression of LRP-positive cells within the perivascular space did not vary significantly between AD and non-AD cases (Fig. 3) . The glia limitans was marked with anti-LRP-CD91 >-chain in nearly all cases, whereas anti-LRP-1704 was not prominent in the glia limitans except for single cases.
Semiquantitative assessment of the LRP occurrence in perivascular astrocytes did not exhibit significant differences in our sample between AD and non-AD cases ( in all 10 AD cases. Four controls were free of SVD. Alzheimer disease cases exhibited SVD more frequently and more widespread as represented by the stage of SVD than controls (Mann-Whitney U test, p G 0.05; Fig. 2D) . Apolipoprotein E-positive SVD lesions were more frequently found in AD cases than in controls (Mann-Whitney U test, p G 0.05; Fig. 2D ). Small vessel disease lesions frequently exhibited apoE-expressing cells in the media and extracellular apoE (Figs. 2E, 4AYC ; Mann-Whitney U test, p G 0.005). There was an overall correlation between the stage of SVD and the exhibition of apoE in the vessel wall (Spearman correlation, r = 0.331; p G 0.05). Double label immunohistochemistry confirmed the expression of apoE in smooth muscle cells of altered vessels (Figs. 4DYF) . Some apoEpositive cells in the vessel wall did not exhibit smooth muscle actin. These cells showed a spindle-shaped morphology and colocalized the CD68 epitope, indicating a macrophage nature of these perivascular cells (Figs. 4GYI) . In addition, extracellular apoE was also seen in SVD lesions (Fig. 4F) . Apolipoprotein E-positive material in the vessel wall was not only seen in cases with severe SVD but also in those with minimal vascular lesions (Figs. 4B, C) . Although cells in the vessel walls were detected with anti-LRP-1704 and anti-LRP-CD91 >-chain (Fig. 4J, K) , the occurrence and distribution of these cells did not differ significantly among the stages of SVD and between AD cases and controls (p = 0.812; LRP >-chain; LRP-1704; Fig. 2F ). Except for 1 AD case with severe CAA, AA deposits were not seen in the vessel walls of basal ganglia vessels.
Amyloid A-protein in perivascular astrocytes was more frequently found in cases with advanced SVD stages than in those with early-stage lesions (Kruskal-Wallis H test, p G 0.05). Apolipoprotein E in the perivascular astrocytes was not associated with SVD (Kruskal-Wallis H test, p = 0.476). Apolipoprotein E ?4 allele carriers did not significantly differ in the vascular apoE and LRP expression from non-?4 carriers (Mann-Whitney U test; p = 0.287Y0.687).
IgG in the Perivascular Space of SVD and AD Cases
To clarify whether plasma leakage into the perivascular space and into the vessel wall can explain the occurrence of the plasma protein apoE in the vessel wall and in the perivascular space, the distribution of human IgG was studied in the basal ganglia. All cases (i.e. controls, SVD, and AD cases) exhibited IgG-positive perivascular macrophages. There was no significant exhibition of IgG in perivascular astrocytes. Immunoglobulin G was also detected in the serum inside the blood vessels (Fig. 3G) . Small amounts of perivascular IgG were seen only in 1 of 4 control cases free of AD and SVD. In SVD and/or AD cases, on the other hand, extracellular IgG was frequently found in the perivascular space and within the vessel wall of arteries with SVD lesions (Figs. 3H, I ).
Semiquantitative assessment of IgG revealed more vessels with IgG-positive lesions in SVD cases when compared with control cases free of SVD (Mann-Whitney U test; p G 0.05; Fig. 2E ). Significant differences in the amount of IgG in the perivascular space among AD and controls were not seen because 16 of 20 non-AD cases exhibited SVD (Mann-Whitney U test, p = 0.142).
Full-Length and C-Terminal Truncated apoE Occur in the Basal Ganglia of AD and Control Cases
Western blot analysis revealed significant amounts of full-length apoE in the supernatant of the basal ganglia tissue lysates. The apoE content varied among all cases without significant differences between AD and control cases (Fig. 5A) . The protein pellet of all analyzed cases contained full-length and C-terminal truncated apoE (Fig. 5B) . All AD cases thereby showed higher levels of C-terminal truncated apoE than of full-length apoE, whereas predominance of C-terminal truncated apoE was seen in 3 control cases and that of full-length apoE was seen in the other 3 (Figs. 5B, C) . The D6E10 anti-apoE antibody is raised against a peptide covering the receptor-binding region of apoE and therefore does not cross-react with C-terminal fragments of apoE but is capable of detecting C-terminal truncated apoE. There were no significant differences in the C-terminal truncated apoE-full-length apoE ratio between APOE ?4 carriers and noncarriers (Mann-Whitney U test, p = 0.508).
DISCUSSION
Our results together with those of our recent studies on animal models (22, 50) show that apoE is not only involved in the perivascular drainage in the pathogenesis of AD but also in that of SVD in the basal ganglia arteries. Therefore, it is tempting to speculate that apoE represents a pathogenetic link between AD and SVD, providing a possible explanation for the previously reported association of AD with SVD (29Y32).
Perivascular apoE and its Relation to AD
In this study, we have shown that apoE occurs in the perivascular space and in perivascular astrocytes around the vessels of the basal ganglia of AD and control individuals. Moreover, in AD cases, some of these apoE-positive perivascular astrocytes contained AA. The AA expression in perivascular astrocytes thereby correlated with the overall expansion of parenchymal and vascular AA deposition, as FIGURE 5 . For Western blot analysis, the supernatant of the basal ganglia tissue lysate and the solubilized pellet was subjected. (A) The supernatant revealed varying degrees of full-length apolipoprotein E (apoE) in controls (j) and Alzheimer disease (AD) cases. Actin was detected as loading control. (B) Within the solubilized pellet, full-length (FL-apoE) and C-terminal truncated apoE (CTT-apoE) were detected. The amounts varied among AD and control samples. The D6E10 anti-apoE antibody detects FL-apoE and apoE-cleavage products containing the receptor-binding domain such as C-terminal truncated apoE, whereas C-terminal fragments cannot be recognized. Actin was detected as loading control. (C) All AD cases used for Western blot analysis exhibited more C-terminal truncated apoE than FL-apoE, whereas in controls, this ratio was variable.
represented by the AA phases in the MTL (44) and the CAA stages (30) , and with that of neurofibrillary changes, as indicated by the Braak stages (2). Combined, our findings in the human brain are in line with previous studies that reported the presence of apoE in perivascular astrocytes and in the perivascular space in the mouse brain (22) . The accumulation of AA within apoE-positive perivascular astrocytes in AD cases point to a possible involvement of these cells in the pathogenesis of AD. This is supported by 1) the capability of astrocytes to take up AA (17); 2) the apoE dependence of this clearance pathway (27); 3) a similar astroglial accumulation of AA in association with different types of amyloid plaques (12, 14Y16, 51); and 4) the contribution of the latter types of plaques to the development of AD-related A-amyloidosis (44) .
The perivascular astrocytes produce apoE and allow drainage of apoE along the perivascular space, as shown in mice overexpressing human apoE driven by an astrocytespecific GFAP promoter (22) . Amyloid A-protein colocalizes apoE in the perivascular space of APP-transgenic mice (22) and of the human brain, as demonstrated here. Thus, AA is presumably drained along perivascular channels bound to apoE. Amyloid A-protein deposition in cortical and leptomeningeal vessels is also associated with the deposition of apoE in AD cases (52) and in APP-transgenic mouse models of AD (22) and further argues in favor of this hypothesis.
The accumulation of AA in apoE-positive perivascular astrocytes suggests an uptake of apoE-linked AA into these cells and to a decreased clearance of these proteins into the perivascular space. The absence of AA-positive perivascular astrocytes in APP-transgenic mice (22) indicates that overproduction of AA not necessarily leads to the accumulation of AA in perivascular astrocytes and argues in favor of clearance deficits that induce the accumulation of AA in perivascular astrocytes in sporadic AD cases. The decreased clearance and subsequent accumulation of AA may be explained by a BBB dysfunction either at the cellular level or at the vascular level, leading to changes in the composition of the perivascular space fluid.
In detail, astrocytes physiologically clear AA across BBB (9) . Lipoprotein receptor-related protein is involved in this clearance process (53, 54) . The LRP-related clearance of AA depends on apoE (26, 27) , which is usually produced in the brain by astrocytes (21) . In AD, BBB clearance of AA is thought to be altered (9, 53) . After this hypothesis, one can assume that the function of BBB astrocytes is specifically altered. One would then expect that either changes in the LRP expression or in apoE distribution would accompany AA deposition. However, there were no morphologic differences in the perivascular apoE distribution and astroglial LRP expression and no differences in the apoE content of the basal ganglia between AD cases and controls, indicating that glial BBB dysfunction with consecutive changes in the glial LRP expression and the perivascular presence of apoE may not be the key factor for the increase in perivascular AA-positive astrocytes. To exclude antibody-specific effects to be responsible for the lack of differences in the cellular LRP expression pattern, we used 2 different antibodies, 1 against the C-terminus of LRP (47) and the other directed against the LRP-CD91 >-chain. The only difference in the staining pattern was a distinct staining of the glia limitans membrane with anti-LRP-CD91 >-chain but not with anti-LRP-1704 directed against the C-terminus. Differences between AD, SVD, and control cases in the LRP staining pattern of the glia limitans were not obvious. Because LRP shedding by metalloproteases has been reported (55), the LRP >-chain-positive material may represent N-terminal shedding products of LRP found in the glia limitans.
A specific accumulation of AA in perivascular astrocytes due to glial BBB alterations is also not likely because morphologically similar AA-containing astrocytes have also been reported elsewhere, that is, in association with different types of amyloid plaques and within the subpial zone of the molecular layer (12, 14Y16, 51) . In so doing, perivascular AA-containing astrocytes may be a secondary result of altered perivascular drainage, rather than a key event for the reduction of cellular AA clearance.
The occurrence of predominantly C-terminal truncated apoE in AD cases (56) indicates significant proteolysis of neuron-derived apoE in AD cases (20) . In the event of sufficient apoE drainage, an accumulation of C-terminal truncated apoE would not be expected. Its predominant accumulation in AD cases therefore argues in favor of alterations of the clearance of apoE in addition to that of AA. As seen in this study, the presence of C-terminal truncated apoE in control cases with minor AD-related pathology points to an early involvement of clearance alterations for apoE in the pathogenesis of AD at least in the basal ganglia.
Previous studies did not find C-terminal truncated apoE in control cortex (56) . Because these studies included only single APOE ?3/3 control cases (56) and were based on cortex tissue, our finding of predominant C-terminal truncated apoE in the basal ganglia in a subset of control cases, also including APOE ?2 and ?4 carriers, does not necessarily contradict these previous reports. The low level of C-terminal truncated apoE in other controls argues in favor of either Bnormal[ variations in the occurrence of C-terminal truncated apoE or initial changes in the equilibrium between full-length and C-terminal truncated apoE. However, the presence of apoE in the brain supports AA deposition (57) and is injurious in supporting the accumulation of AA in the ubiquitin/ proteasome system (58) . In doing so, the increased degradation of apoE, as seen here in all AD cases, may indicate that apoE occupies the ubiquitin/proteasome system and thereby induces the intracellular accumulation of AA (58) .
apoE in SVD
Our second finding was the presence of apoE in the vessel wall of basal ganglia arteries with SVD. Here, apoE was seen in altered smooth muscle cells and in the extracellular space of the lamina media. In single cases, the occurrence of apoE seemed to be a very early sign of SVD. Healthy vessels did not exhibit apoE, as documented here and already reported by others (59) . The extent of vessels with apoE-positive cells and/or extracellular apoE in the basal ganglia correlated with the increasing severity of SVD. Regardless of the particular role of apoE, its simple presence in SVD-affected vessels and its correlation with the stage of SVD indicate that apoE is involved in the pathogenesis of SVD. This is supported by the association of SVD with the APOE ?4 allele, as found by other authors (60) , and the role of apoE in the inhibition of smooth muscle cell proliferation and migration (61, 62) . To clarify whether apoE in the vessel wall is produced by local cells or represents plasma leakage into the altered vessel wall, we analyzed whether IgG (a second plasma protein, which is neither produced by smooth muscle cells nor by brain cells) also occurred in the SVD-related vessel wall lesions and in the perivascular space. The detection of IgG within SVD lesions in the vessel wall and its occurrence in the perivascular spaces of SVD and AD patients but not in non-SVD controls strongly suggests a leakage of plasma proteins, including apoE and IgG, into the vessel wall and the perivascular space in SVD and AD patients. This hypothesis is supported by the detection of other serum proteins, including the lipoprotein apoB in association with parenchymal and/or vascular AA deposits and in association with cortical vessels in vascular dementia (63Y68). Moreover, SVD leads to alterations of the vessel wall similar to hypertensive arteriopathy, and it is obvious that plasma proteins similarly enter the altered vessel wall as reported for hypertensive arteriopathy (33, 34) . Further evidence that such vascular lesions support AD-related AA deposition has been recently provided by the detection of AA deposits in mouse models of hypertension (69) .
The presence and extent of SVD are increased in AD cases compared with nondemented controls (29, 30) and suggests a pathogenetic link between AD and SVD. The association of both AD and SVD with the ?4 allele (23, 60) and the presence of apoE in senile plaques (52) and in SVDaffected vessels, as shown here, provide evidence that this link may be apoE. If this hypothesis is true, the question arises whether AD causes SVD or vice versa, or whether apoE triggers both diseases independently.
Studies in aged APP-transgenic and wild-type mice revealed no SVD-related changes, indicating that SVD is not induced by AD-related plaque deposition and AA drainage along perivascular spaces (50) . Apolipoprotein E knockout mice reveal vascular changes and are a well-known animal model for atherosclerosis (70) . The presence of apoE is assumed to be protective for the vessel wall (59) and also prevents BBB dysfunction (71, 72) . It is therefore unlikely that apoE triggers SVD, but the occurrence of apoE may either indicate the upregulation of a feedback mechanism for the inhibition of smooth muscle cell and endothelial cell proliferation and migration (59, 61, 62) or plasma protein leakage. Our finding of an IgG leakage into the vessel wall and into the perivascular space of SVD and AD cases and FIGURE 6. Schematic representation of small vessel disease (SVD)Yinduced plasma protein leakage and its hypothetical consequences. In the normal brain, there is significant efflux of cerebral apolipoprotein E (apoE) into the perivascular drainage channels, as also shown in transgenic mice producing apoE driven by the glia-specific glial fibrillary acidic protein promoter (upper panel) (22) . Physiologically produced amyloid A-protein (AA) is cleared together with apoE into these channels, and AA deposits do not develop. Small vessel disease lesions allow leakage of plasma-proteins into the vessel wall and into the perivascular space (lower panel) (34, 64) . Although the glia limitans is still intact, apoE and immunoglobulin G occur in the vessel wall and in the perivascular space of cerebral arteries may therefore compete with brain-derived clearance of apoE from perivascular astrocytes into the perivascular drainage channels. In doing so, one would expect that less AA and apoE can be cleared by perivascular drainage. Apolipoprotein E may undergo proteolytic cleavage, and C-terminal truncated apoE predominates in the brain as shown here. The accumulation of AA in the brain finally results in the deposition of AA and in the development of Alzheimer disease (AD). This hypothesis is supported by the association of the overall expansion of SVD with the development of AD (29, 30) .
previously published studies on the presence of plasma proteins, including the lipoprotein apoB, in the AD and vascular dementia brain (63Y68) support the latter explanation. Because drainage of cerebral apoE and apoE-linked AA into the perivascular space is one of its physiologic clearance mechanisms (22) , it is tempting to speculate that leakage of plasma proteins, including apoE, into the perivascular space due to SVD-induced plasma protein leakage raises the threshold for the apoE clearance from the brain. One would expect that the apoE-linked astroglial clearance of AA from brain is reduced and thereby leads to the accumulation of AA in perivascular astrocytes (Fig. 6 ) and to the proteolysis of cerebral apoE as indicated by the predominant occurrence of C-terminal truncated apoE in AD cases. Thus, it is tempting to speculate that the competition for perivascular apoE drainage may reduce the cerebral apoE and apoE-linked AA clearance in the event that additional apoE due to SVDrelated plasma protein leakage needs to be drained and disables the perivascular drainage equilibrium (Fig. 6) .
CONCLUSIONS
In the context of recent studies in mouse models (22, 50) , our results indicate that 1) apoE plays an important role in the perivascular drainage of the human brain, 2) apoE is involved in the pathogenesis of SVD, and 3) apoE may provide a link between SVD and AD.
